The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma
Ayako Kamiunten, Daisuke Morishita, Takuro Kameda, Midori Sugiyama, Shunsuke Ebara, Yasunori Kogure, Akio Mizutani, Takaharu Hirayama, Tomohiro Kawamoto, Yotaro Ochi, Kotaro Shide, Hidekazu Tokuhara, Toshio Tanaka, Hiroshi Banno, Yasuyoshi Arikawa, Takamitsu Maru, Hideyuki Oki, Akinori Yoda, Yuki Tahira, Ryoma Ikeda, Kengo Matsumoto, Masayoshi Karasawa, Keiichi Akizuki, Masaaki Sekine, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Hideki Yamaguchi, Hiroo Hasegawa, Yoshitaka Imaizumi, Jun-ichirou Yasunaga, Masao Matsuoka, Makoto Yoshimitsu, Kenji Ishitsuka, Keisuke Kataoka, Seishi Ogawa, Kazuya Shimoda · 2026
Read The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma by Ayako Kamiunten, Daisuke Morishita, Takuro Kameda, Midori Sugiyama, Shunsuke Ebara, Yasunori Kogure, Akio Mizutani, Takaharu Hirayama, Tomohiro Kawamoto, Yotaro Ochi, Kotaro Shide, Hidekazu Tokuhara, Toshio Tanaka, Hiroshi Banno, Yasuyoshi Arikawa, Takamitsu Maru, Hideyuki Oki, Akinori Yoda, Yuki Tahira, Ryoma Ikeda, Kengo Matsumoto, Masayoshi Karasawa, Keiichi Akizuki, Masaaki Sekine, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Hideki Yamaguchi, Hiroo Hasegawa, Yoshitaka Imaizumi, Jun-ichirou Yasunaga, Masao Matsuoka, Makoto Yoshimitsu, Kenji Ishitsuka, Keisuke Kataoka, Seishi Ogawa, Kazuya Shimoda (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427568.txt.
Description
Ayako Kamiunten heads a 2026 study on a protein called MALT1 in adult T-cell leukemia and lymphoma. This fast-growing blood cancer follows infection with a virus named HTLV-1, sometimes decades later. Many of these cancers carry faults in the signaling chain that MALT1 helps run. The team built a new drug, coded CRD-1441551, that blocks MALT1's cutting action with precision.
They tested the drug on three cancer cell lines and five tumor models grown from patient tissue in mice. Two models shrank strongly, three responded modestly, and three did not respond. Models with MALT1 switched on and its downstream signals running hot did best. The results suggest a targeted option for a defined subgroup of a cancer that now has few good choices.
Catalog record
| CREATOR | Ayako Kamiunten, Daisuke Morishita, Takuro Kameda, Midori Sugiyama, Shunsuke Ebara, Yasunori Kogure, Akio Mizutani, Takaharu Hirayama, Tomohiro Kawamoto, Yotaro Ochi, Kotaro Shide, Hidekazu Tokuhara, Toshio Tanaka, Hiroshi Banno, Yasuyoshi Arikawa, Takamitsu Maru, Hideyuki Oki, Akinori Yoda, Yuki Tahira, Ryoma Ikeda, Kengo Matsumoto, Masayoshi Karasawa, Keiichi Akizuki, Masaaki Sekine, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Hideki Yamaguchi, Hiroo Hasegawa, Yoshitaka Imaizumi, Jun-ichirou Yasunaga, Masao Matsuoka, Makoto Yoshimitsu, Kenji Ishitsuka, Keisuke Kataoka, Seishi Ogawa, Kazuya Shimoda |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60542 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |